Qualitas Health partners with Lipa Pharmaceuticals to distribute Almega PL in Australia and New Zealand

Almega PL is a vegetarian, EPA-rich, polar lipid-structured omega-3 oil

Qualitas Health has signed an exclusive distribution agreement with Lipa Pharmaceuticals for the sale of its Almega PL omega-3 ingredient in Australia and New Zealand.

Lipa Pharmaceuticals a leading Australian contract manufacturer of dietary supplements and over-the-counter pharmaceutical products, including tablets, soft gelatin capsules, two-piece hard gelatin capsules, powders, liquids and creams. Lipa will obtain the appropriate regulatory approvals from the Australian Therapeutic Goods Administration (TGA), provide logistic and sales support as well as offering dosage-form solutions.

Almega PL, manufactured by Qualitas Health, is a vegetarian, EPA-rich, polar lipid-structured omega-3 oil. Sourced from Nannochloropsis oculata, a non-GMO strain of microalgae selected for its high level of EPA omega-3 and unique polar-lipid structure, it contains omega-3 fatty acids with phospholipids and glycolipids that are said to provide superior absorption and digestibility. Farmed microalgae are a source of omega-3s that do not deplete the fragile marine ecosystem, the company says.

Almega PL is sustainably produced, using natural sunlight, non-arable land and low-energy processes.

'This agreement extends our Almega PL sales efforts to a large, vibrant and growing omega-3 market which is increasingly demanding a vegetarian and sustainable alternative,' said Yuri Shoshan, CEO of Qualitas Health.